Clinical Outcomes of Carotid Endarterectomy in Patients With Carotid Artery Tandem Lesions  by Han, Y. et al.
Abstracts
Gregory L. Moneta, MD, Section EditorClinical Outcomes of Carotid Endarterectomy in Patients
With Carotid Artery Tandem Lesions
Han Y, Park H, Kwon SU, et al. Stroke 2014;45:3443-6.
Conclusions: Patients undergoing carotid endarterectomy with the
diagnosis of tandem carotid stenosis by contrast-enhanced magnetic reso-
nance angiography have similar rates of stroke and death with and without
tandem stenosis.
Summary: There have been previous studies evaluating the outcomes
of carotid endarterectomy in patients with both intracranial and extracranial
carotid artery disease. Most such studies were published more than 15 years
ago using intra-arterial digital subtraction angiography for diagnosis of ca-
rotid lesions. The authors sought to reevaluate outcomes of carotid endar-
terectomy in patients with extracranial and combined intracranial carotid
artery stenosis in the modern era where the use of noninvasive diagnostic
modalities such as Duplex ultrasonography and contrast-enhanced magnetic
resonance angiography are primarily used in the planning of carotid endar-
terectomy. There were 647 consecutive patients who underwent CEA be-
tween January 2001 and December 2010. Tandem stenosis, deﬁned as a
signiﬁcant carotid bifurcation stenosis and identiﬁable stenosis of $50% of
any downstream distal cerebral artery was identiﬁed in 92 patients
(14.2%) by contrast enhanced magnetic resonance angiography. Patients
with and without tandem stenosis were compared in terms of CEA out-
comes. Primary end point was the composite of any stroke, myocardial
infarction, or death during the periprocedular period or ipsilateral stroke
within 4 years after the CEA. The two groups did not differ in terms of esti-
mated 4-year primary endpoint rates (8.7% vs 3.8%; P ¼ .07) for ipsilateral
stroke-free (P ¼ .56), any strokeefree (P ¼ .89), or overall survival
(P ¼ .41).
Comment: The study conﬁrms the frequency with which tandem le-
sions are observed in patients undergoing CEA (14.2%) and the fact that
tandem lesions are not associated with an increased risk of ipsilateral stroke
during follow-up after CEA. The only really unique feature of the study is
that it is more modern than previous studies and that the diagnosis of intra-
cranial stenosis was made in a different fashion using MRA rather than cath-
eter based contrast angiography.Global Sodium Consumption and Death From
Cardiovascular Causes
Mozaffarian D, Fahimi S, Singh GM, et al. N Engl J Med 2014;371:624-34.
Conclusions: There were 1.65 million deaths from cardiovascular
causes in 2010 attributable to sodium consumption above a reference level
of 2.0 g per day.
Summary: Increased intake of dietary sodium is associated with
elevated blood pressure and adverse cardiovascular outcomes (Frieden
TR et al, N Engl J Med 2011;365:e27). However, global effects of sodium
consumption and the effects according to age, sex, and country have not
been clearly established. The authors collected data from surveys on so-
dium intake as determined by urinary excretion and diet in persons from
66 countries (accounting for 74.1% of adults throughout the world).
The data was then used to quantify global consumption of sodium accord-
ing to age, sex, and country. Effects of sodium on blood pressure accord-
ing to age, race, and the presence or absence of hypertension were
calculated from data in a new meta-analysis of 107 randomized interven-
tions, and the effects of blood pressure on cardiovascular mortality,
according to age, were calculated from a meta-analysis of cohorts.
Cause-speciﬁc mortality was then derived from the Global Burden of Dis-
ease Study 2010. Using comparative risk assessment an estimate of the car-
diovascular effects of current sodium intake as compared with the
referenced intake of 2.0 g of sodium per day according to age, sex, and
country was determined. In 2010 the estimated mean level of global so-
dium consumption was 3.95 g per day, and the regional mean levels
ranged from 2.18 to 5.51 g per day. Globally, 1.65 million annual deaths
from cardiovascular causes (95% uncertainty interval [conﬁdence interval],
1.10 million to 2.22 million) were attributed to sodium intake above the
reference level; 61.9% of these deaths occurred in men and 38.1% occurred
in women. These deaths accounted for nearly 1of every 10 deaths from
cardiovascular causes (9.5%). Four of every 5 deaths (84.3%) occurred inlow- and middle-income countries and two of every ﬁve deaths (40.4%)
were premature (before 70 years of age).
Comment: The data indicate that no region and few countries are
spared from the adverse effect of increased sodium consumption on cardio-
vascular death. The data, however, depends upon extrapolating the effects
of sodium on blood pressure to cardiovascular risks. Although this is not
deﬁnitively established, the effect on cardiovascular disease from hyperten-
sion and the effects of sodium consumption on hypertension are supported
by extensive experimental and demographic evidence. A meta-analysis of 37
trials has shown no signiﬁcant adverse effects on blood lipid levels, catechol-
amine levels or renal function from decreased sodium consumption (Aburto
NJ et al, BMJ 2013;346:f1326). Therefore it appears there is nothing to be
lost and potentially much to be gained by decreasing sodium consumption
for adults to less than 2 g per day.Improved Quality of Life After 1 Year With an Invasive
Versus a Noninvasive Treatment Strategy in Claudicants:
One-Year Results on the Invasive Revascularization or
Not in Intermittent Claudication (IRONIC) Trial
Nordanstig J, Taft C, Hensäter M, et al. Circulation 2014;130:939-47.
Conclusions: An invasive treatment strategy improves health-related
quality of life and intermittent claudication distance after 1 year in patients
with stable lifestyle-limiting claudication receiving current medical
management.
Summary: Patients with intermittent claudication are at increased risk
for cardiovascular events, cerebrovascular events and premature death but
are at low risk of limb loss. Many claudicants will respond with increased
walking distance with exercise training, thus risk factor modiﬁcation and
medical treatment and exercise training are standard and accepted ﬁrst-
line treatments of patients with intermittent claudication (IC). However ex-
ercise training under supervision is not often available for many patients and
many others are poorly compliant with supervised exercise. Evidence for the
effectiveness of invasive treatment for intermittent claudication is relatively
sparse. Most studies evaluating invasive treatment have used selective inclu-
sion criteria enrolling patients on the basis of vascular lesions (ie, in speciﬁc
vessel segments or lesions of certain length and severity with suitable anat-
omy for endovascular treatment). A long list of exclusion criteria in such
studies has made it difﬁcult to generalize results to the majority of patients
with intermittent claudication. Based on all of this the authors sought to
perform what they term “a real world” study to test the hypothesis that
an invasive (surgical or endovascular) treatment strategy compared with
continued medical therapy would improve health-related quality of life in
relatively unselected IC patients already receiving best medical treatment
and structured (nonsupervised) exercise training advice. Patients with inter-
mittent claudication underwent clinical and ultrasound assessment and
those requesting treatment for claudication were then randomly assigned
to invasive (n ¼ 79) or noninvasive (n ¼ 79) treatment groups. The primary
endpoint was health-related quality of life after 1 year assessed with the
Medical Outcomes Study Short Form 36 version 1 and Vascular Quality
of Life Questionnaire. Secondary endpoints included walking distance on
a graded treadmill. The Medical Outcomes Short Form 36 version 1 phys-
ical components and 2 Medical Outcomes Study Short Form 36 version
1 physical subscales improved signiﬁcantly more in the invasive vs the nonin-
vasive group (P < .001). Vascular Quality of Life Questionnaire score
(P < .01) and 3 of 5 domain scores improved signiﬁcantly more in the inva-
sive vs the noninvasive group. Intermittent claudication distance improved
more in the invasive (+124 m) vs the noninvasive (+50 m) group (P ¼
.003). Change in maximum walking distance was not signiﬁcantly different
between groups.
Comment: There are several innovative elements in this trial’s study
design, the primary one of which is to use the health-related quality of
life as the primary end point. Most claudication trials have used patency
of reconstructions, and treadmill walking distance as primary endpoints in
evaluation of treatments for claudication. Beneﬁts in health-related quality
of life may include many elements and not just leg symptoms. The concept
of patient-centered outcomes is becoming increasingly prevalent in clinical
trials. To test the unique approach presented in this trial it also will need
to be evaluated in additional studies incorporating longer follow-up and567
